Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 12, 2022 08:00 ET | Source: Vor Biopharma

Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer

CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief...
October 11, 2022 08:00 ET | Source: Vor Biopharma

Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment

-Multiplex deletion of myeloid antigens CD33 and CLL-1 or CD33 and CD123 in human hematopoietic stem cells resulted in long-term engraftment and persistence of editing -Data presented at European...
September 28, 2022 08:00 ET | Source: Vor Biopharma

Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters

CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the opening of its new in-house clinical...
September 06, 2022 16:15 ET | Source: Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
August 11, 2022 16:15 ET | Source: Vor Biopharma

Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update

Initial clinical data for patients treated with Vor Bio’s engineered HSC candidate VOR33 on track for Q4 2022In-house manufacturing facility in Cambridge, MA operational in Q4 2022Data presented at...
August 01, 2022 08:00 ET | Source: Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
June 10, 2022 08:00 ET | Source: Vor Biopharma

Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for treatment of acute myeloid leukemia Dual edited...
June 01, 2022 08:00 ET | Source: Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
May 12, 2022 16:15 ET | Source: Vor Biopharma

Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update

Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022Data presented at Keystone Symposia demonstrates significant advancement of novel multiplex editing...
May 05, 2022 08:00 ET | Source: Vor Biopharma

Vor to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will...